AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: BGF MDI HFO 320/14.4/9.6 μgDrug: BGF MDI HFA 320/14.4/9.6 μg
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 559
- Registration Number
- NCT05573464
- Locations
- 🇬🇧
Research Site, Thetford, United Kingdom
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Recruiting
- Conditions
- Breast NeoplasmsBreast CancerNeoplasm Metastasis
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT05573893
- Locations
- 🇩🇪
Research Site, Zittau, Germany
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT05573724
- Locations
- 🇷🇴
Research Site, Cluj-Napoca, Romania
A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT05569421
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
eVusheld Assessment reaL wORld Effectiveness in DoD Health System
Not yet recruiting
- Conditions
- COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6000
- Registration Number
- NCT05569408
- Locations
- 🇺🇸
Research Site, Bethesda, Maryland, United States
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
Phase 1
Completed
- Conditions
- NAFLDNonalcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisNASHNon-alcoholic Fatty Liver DiseaseFatty Liver, Nonalcoholic
- Interventions
- Drug: AZD7503 Intervention
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT05560607
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 210
- Registration Number
- NCT05557838
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT05557695
- Locations
- 🇬🇧
Research Site, Wigan, United Kingdom
PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Combination Product: PT027Combination Product: PT007
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT05555290
- Locations
- 🇺🇸
Research Site, Columbia, Maryland, United States
A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT05551897
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath